Evaluation of inhibition of toll- like receptors 4 and 9 on liver fibrosis initiation in mice / (Record no. 169599)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05900namaa22004211i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20241226174611.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 241221s2023 |||a|||f m||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 590 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 590 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.12.21.M.Sc.2023.Ah.E |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Ahmed Mohamed Youssef El Seid, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Evaluation of inhibition of toll- like receptors 4 and 9 on liver fibrosis initiation in mice / |
| Statement of responsibility, etc. | by Ahmed Mohamed Youssef El Seid ; supervision of Prof. Azza Mohamed Elamir, Prof. Alyaa Ahmed Farid, Prof. Ibrahim Rabae Shalash. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | / تقييم تثبيط شبيه مستقبلات تول ٩،٤ في بدء تليف الكبد في الفئران |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2023. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 50 pages + (40 leaves) : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (M.Sc)-Cairo University, 2023. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 75-98. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Nowadays, liver fibrosis is a major health problem that can lead to cirrhosis and liver cancer. The estimated mortality rate is 1.5 million death/year. Toll like receptors play an important role in liver fibrosis progression. Where, their activation leads to the transcription of inflammatory mediators as IL-6 and TNF-α. Our study was designed to investigate the effect of toll like receptors (TLR)4 and TLR9 antagonist individually or in combination for the treatment of liver fibrosis. CCL4 was used as an agent for producing fibrotic liver models in mice. Mice received 100µl of CCL4, at a dose of 0.4 ml/kg, dissolved in olive oil, by oral administration twice a week for 3 successive weeks. Animals continued to receive the same dose of CCL4 throughout the study. Mice received 100 µl of TLR4 or TLR9 antagonist at a concentration of 70µg/ml or 2.85 µg/ml, respectively, by oral administration three times a week. Mice treated with combined TLR4 and TLR9 antagonists were given 100µl (equal volume of TLR 4 and TLR9 antagonist) 3 times for a week. Our results proved that blocking of both TLR4 and TLR9 can be an ideal anti-fibrotic therapy. Combined TLR4 and TLR9 antagonists administration reduced inflammatory cytokines, decreased collagen deposition without affecting normal extracellular matrix synthesis, and promoted both fibrosis regression and liver regeneration. The use of combined TLR4 and TLR9 antagonists has succeeded in the inhibition of CCL4 induced liver fibrosis progression. Furthermore, liver regeneration with a decrease in collagen fibers was observed in liver sections from mice treated with combined TLR4 and TLR9 antagonists more than those of other treated groups (TLR4 antagonist group IV and TLR9 antagonist group V). |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | في الوقت الحاضر ، يعد تليف الكبد مشكلة صحية كبيرة يمكن أن تؤدي إلى تليف الكبد وسرطان الكبد. معدل الوفيات المقدر هو 1.5 مليون حالة وفاة / سنة. تلعب المستقبلات الشبيهة بالحصيلة دورًا مهمًا في تطور تليف الكبد. حيث يؤدي تنشيطها إلى نسخ الوسطاء الالتهابيين كـ IL-6 و TNF-α. تم تصميم دراستنا للتحقيق في تأثير مستقبلات مثل (TLR) 4 ومضاد TLR9 بشكل فردي أو مجتمعة لعلاج تليف الكبد. تم استخدام CCL4 كعامل لإنتاج نماذج الكبد الليفية في الفئران. تلقت الفئران 100 ميكرولتر من CCL4 بجرعة 0.4 مل / كجم مذابة في زيت الزيتون عن طريق الفم مرتين في الأسبوع لمدة 3 أسابيع متتالية. واصلت الحيوانات تلقي نفس جرعة CCL4 طوال فترة الدراسة. تلقت الفئران 100 ميكرولتر من مضاد TLR4 أو TLR9 بتركيز 70 ميكروغرام / مل أو 2.85 ميكروغرام / مل ، على التوالي ، عن طريق الفم ثلاث مرات في الأسبوع. أعطيت الفئران التي عولجت بمضادات TLR4 و TLR9 مجتمعة 100 ميكرولتر (حجم مساوٍ لمضاد TLR 4 و TLR9) 3 مرات لمدة أسبوع. أثبتت نتائجنا أن حجب كل من TLR4 و TLR9 يمكن أن يكون علاجًا مثاليًا مضادًا للليف. خفضت إدارة مضادات TLR4 و TLR9 السيتوكينات الالتهابية ، وقللت ترسب الكولاجين دون التأثير على تخليق المصفوفة خارج الخلية ، وعززت كل من انحدار التليف وتجديد الكبد. نجح استخدام مضادات TLR4 و TLR9 مجتمعة في تثبيط تطور تليف الكبد الناجم عن CCL4. علاوة على ذلك ، لوحظ تجديد الكبد مع انخفاض في ألياف الكولاجين في أقسام الكبد من الفئران المعالجة بمضادات TLR4 و TLR9 أكثر من تلك الموجودة في المجموعات المعالجة الأخرى (مجموعة مناهضات TLR4 IV ومجموعة مناهضة TLR9 V). |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Zoology |
| Source of heading or term | qrmak |
| 653 #0 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Liver fibrosis |
| -- | cytokines |
| -- | CCL4 |
| -- | TLR antagonist. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Azza Mohamed Elamir |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Alyaa Ahmed Farid |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ibrahim Rabae Shalash |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2023 |
| Supervisory body | Azza Mohamed Elamir |
| -- | Alyaa Ahmed Farid |
| -- | Ibrahim Rabae Shalash |
| Universities | Cairo University |
| Faculties | Faculty of Science |
| Department | Department of Zoology |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Huda |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 21.12.2024 | 89544 | Cai01.12.21.M.Sc.2023.Ah.E | 01010110089544000 | 21.12.2024 | 21.12.2024 | Thesis |